SMN1 and pulmonary arterial hypertension: Notably, 36% to 59% of patients with MCTD are reported to be positive for anti-SMN antibodies, which have been linked to clinical manifestations including interstitial lung disease (ILD), pulmonary arterial hypertension (PAH), myocarditis, and lower gastrointestinal involvement [8, 9].